Effectiveness of high-dose riboflavin in migraine prophylaxis: A randomized controlled trial

J. Schoenen, J. Jacquy, Marc E Lenaerts

Research output: Contribution to journalArticle

363 Citations (Scopus)

Abstract

A deficit of mitochondrial energy metabolism may play a role in migraine pathogenesis. We found in a previous open study that high-dose riboflavin was effective in migraine prophylaxis. We now compared riboflavin (400 mg) and placebo in 55 patients with migraine in a randomized trial of 3 months duration. Using an intention-to-treat analysis, riboflavin was superior to placebo in reducing attack frequency (p = 0.005) and headache days (p = 0.012). Regarding the latter, the proportion of patients who improved by at least 50%, i.e. 'responders,' was 15% for placebo and 59% for riboflavin (p = 0.002) and the number-needed-to-treat for effectiveness was 2.3. Three minor adverse events occurred, two in the riboflavin group (diarrhea and polyuria) and one in the placebo group (abdominal cramps). None was serious. Because of its high efficacy, excellent tolerability, and low cost, riboflavin is an interesting option for migraine prophylaxis and a candidate for a comparative trial with an established prophylactic drug.

Original languageEnglish (US)
Pages (from-to)466-470
Number of pages5
JournalNeurology
Volume50
Issue number2
StatePublished - Feb 1998
Externally publishedYes

Fingerprint

Riboflavin
Migraine Disorders
Randomized Controlled Trials
Placebos
Polyuria
Numbers Needed To Treat
Intention to Treat Analysis
Colic
Energy Metabolism
Headache
Diarrhea
Costs and Cost Analysis
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Effectiveness of high-dose riboflavin in migraine prophylaxis : A randomized controlled trial. / Schoenen, J.; Jacquy, J.; Lenaerts, Marc E.

In: Neurology, Vol. 50, No. 2, 02.1998, p. 466-470.

Research output: Contribution to journalArticle

@article{3592cdc94ea34c6190b48e085860ffdb,
title = "Effectiveness of high-dose riboflavin in migraine prophylaxis: A randomized controlled trial",
abstract = "A deficit of mitochondrial energy metabolism may play a role in migraine pathogenesis. We found in a previous open study that high-dose riboflavin was effective in migraine prophylaxis. We now compared riboflavin (400 mg) and placebo in 55 patients with migraine in a randomized trial of 3 months duration. Using an intention-to-treat analysis, riboflavin was superior to placebo in reducing attack frequency (p = 0.005) and headache days (p = 0.012). Regarding the latter, the proportion of patients who improved by at least 50{\%}, i.e. 'responders,' was 15{\%} for placebo and 59{\%} for riboflavin (p = 0.002) and the number-needed-to-treat for effectiveness was 2.3. Three minor adverse events occurred, two in the riboflavin group (diarrhea and polyuria) and one in the placebo group (abdominal cramps). None was serious. Because of its high efficacy, excellent tolerability, and low cost, riboflavin is an interesting option for migraine prophylaxis and a candidate for a comparative trial with an established prophylactic drug.",
author = "J. Schoenen and J. Jacquy and Lenaerts, {Marc E}",
year = "1998",
month = "2",
language = "English (US)",
volume = "50",
pages = "466--470",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Effectiveness of high-dose riboflavin in migraine prophylaxis

T2 - A randomized controlled trial

AU - Schoenen, J.

AU - Jacquy, J.

AU - Lenaerts, Marc E

PY - 1998/2

Y1 - 1998/2

N2 - A deficit of mitochondrial energy metabolism may play a role in migraine pathogenesis. We found in a previous open study that high-dose riboflavin was effective in migraine prophylaxis. We now compared riboflavin (400 mg) and placebo in 55 patients with migraine in a randomized trial of 3 months duration. Using an intention-to-treat analysis, riboflavin was superior to placebo in reducing attack frequency (p = 0.005) and headache days (p = 0.012). Regarding the latter, the proportion of patients who improved by at least 50%, i.e. 'responders,' was 15% for placebo and 59% for riboflavin (p = 0.002) and the number-needed-to-treat for effectiveness was 2.3. Three minor adverse events occurred, two in the riboflavin group (diarrhea and polyuria) and one in the placebo group (abdominal cramps). None was serious. Because of its high efficacy, excellent tolerability, and low cost, riboflavin is an interesting option for migraine prophylaxis and a candidate for a comparative trial with an established prophylactic drug.

AB - A deficit of mitochondrial energy metabolism may play a role in migraine pathogenesis. We found in a previous open study that high-dose riboflavin was effective in migraine prophylaxis. We now compared riboflavin (400 mg) and placebo in 55 patients with migraine in a randomized trial of 3 months duration. Using an intention-to-treat analysis, riboflavin was superior to placebo in reducing attack frequency (p = 0.005) and headache days (p = 0.012). Regarding the latter, the proportion of patients who improved by at least 50%, i.e. 'responders,' was 15% for placebo and 59% for riboflavin (p = 0.002) and the number-needed-to-treat for effectiveness was 2.3. Three minor adverse events occurred, two in the riboflavin group (diarrhea and polyuria) and one in the placebo group (abdominal cramps). None was serious. Because of its high efficacy, excellent tolerability, and low cost, riboflavin is an interesting option for migraine prophylaxis and a candidate for a comparative trial with an established prophylactic drug.

UR - http://www.scopus.com/inward/record.url?scp=0031909628&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031909628&partnerID=8YFLogxK

M3 - Article

C2 - 9484373

AN - SCOPUS:0031909628

VL - 50

SP - 466

EP - 470

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 2

ER -